Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
CervoMed Inc.
organization3 mentionslast seen Oct 29, 2026
Clinical-stage biotechnology company developing treatments for age-related brain disorders.
Relationships 7
- CervoMed Inc.developsneflamapimod99% confidence3 sources
- CervoMed Inc.employsWilliam Elder99% confidence3 sources
- CervoMed Inc.employsJohn Alam99% confidence2 sources
- CervoMed Inc.employsJohn J. Alam97% confidence1 source
- CervoMed Inc.developsneflamapimod 50 mg oral tablet formulation93% confidence1 source
- CervoMed Inc.authoredA Phase 2b Randomized Clinical Trial of the Oral p38α Inhibitor Neflamapimod in Dementia with Lewy Bodies (DLB)85% confidence1 source
- CervoMed Inc.authoredTargeting Pro-Inflammatory Interleukin-1 Beta Signaling to Modulate Neuroinflammatory Processes Associated with Cognitive Decline in Dementia with Lewy Bodies80% confidence1 source
Relationship
CervoMed Inc.authoredA Phase 2b Randomized Clinical Trial of the Oral p38α Inhibitor Neflamapimod in Dementia with Lewy Bodies (DLB)
85% confidence1 supporting mentions
Either name opens that entity’s relationships.
Sources 1